Patents by Inventor Kyle E. Watters

Kyle E. Watters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of Cas9 polypeptide activity and methods of use thereof
    Patent number: 11795208
    Abstract: The present disclosure provides polypeptides that inhibit activity of a CRISPR/Cas effector polypeptide, nucleic acids encoding the polypeptides, and systems comprising the polypeptides and/or nucleic acids encoding the polypeptides. The present disclosure provides methods of inhibiting activity of a CRISRP/Cas effector polypeptide.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: October 24, 2023
    Assignee: The Regents of the University of California
    Inventors: Jennifer A Doudna, Kyle E. Watters, Christof Fellmann, Haridha Shivram
  • PROTEINS THAT INHIBIT CAS12A (CPF1), A CRIPR-CAS NUCLEASE
    Publication number: 20210363206
    Abstract: Cas12a-inhibiting polypeptides and methods of their use are provided.
    Type: Application
    Filed: June 17, 2019
    Publication date: November 25, 2021
    Inventors: Nicole Blackburn-Marino, Joseph Bondy-Denomy, Kyle E. Watters, Jennifer A. Doudna
  • MODULATORS OF CAS9 POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210340199
    Abstract: The present disclosure provides AcrIIA7 polypeptides, nucleic acids encoding the AcrIIA7 polypeptides, and kits comprising the AcrIIA7 polypeptides and/or nucleic acids encoding the ACRIIA7 polypeptides. The present disclosure provides methods of inhibiting an activity of a Cas9 polypeptide.
    Type: Application
    Filed: September 9, 2019
    Publication date: November 4, 2021
    Inventors: Jennifer A. Doudna, Kyle E. Watters, Haridha Shivram, Christof Fellmann
  • MODULATORS OF CAS9 POLYPEPTIDE ACTIVITY AND METHODS OF USE THEREOF
    Publication number: 20210095004
    Abstract: The present disclosure provides polypeptides that inhibit activity of a CRISPR/Cas effector polypeptide, nucleic acids encoding the polypeptides, and systems comprising the polypeptides and/or nucleic acids encoding the polypeptides. The present disclosure provides methods of inhibiting activity of a CRISRP/Cas effector polypeptide.
    Type: Application
    Filed: September 30, 2020
    Publication date: April 1, 2021
    Inventors: Jennifer A. Doudna, Kyle E. Watters, Christof Fellmann, Haridha Shivram